ANTX News and Press, AN2 Therapeutics Inc.

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...

2024-05-15 10:42:04 ET More on AN2 Therapeutics Spotlight On Nvidia, Walmart, Palo Alto Networks And CAGNY Conference AN2 Therapeutics reports FY results Seeking Alpha’s Quant Rating on AN2 Therapeutics Historical earnings data for AN2 Therapeutics ...

Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determi...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

2024-04-23 11:37:17 ET Summary Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential. Spero has excellent downside protection and additional upside from ...

2024-04-22 16:53:54 ET Gainers: Oportun Financial  ( OPRT ) +5% . Humacyte ( HUMA ) +2% . Revance Therapeutics ( RVNC ) +2% . Office Properties Income  ( OPI ) +2% . Axcelis Technologies ( ACLS ) +1% . Losers: C...

2024-04-02 05:30:04 ET JMP Securities analyst issues OUTPERFORM recommendation for ANTX on April 2, 2024 02:23AM ET. ANTX was trading at $3.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recom...

2024-03-29 06:57:13 ET More on AN2 Therapeutics Spotlight On Nvidia, Walmart, Palo Alto Networks And CAGNY Conference AN2 Therapeutics reports FY results AN2 Therapeutics extends losses as Leerink cuts on trial setback Seeking Alpha’s Quant Rating on A...

2024-03-28 17:11:08 ET More on AN2 Therapeutics Spotlight On Nvidia, Walmart, Palo Alto Networks And CAGNY Conference AN2 Therapeutics extends losses as Leerink cuts on trial setback Biggest stock movers today: Diamondback Energy, Joby Aviation, monday.com, and more ...

Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and inve...